News brief.
FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants
If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.
Read More
FDA Approves First Pediatric Indication for Blockbuster Eylea
Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.
FDA Accepts BLA for RSV Prevention in Infants
Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.
Wegovy Approved for Teens; Supply May be Delayed
Wegovy is a once-weekly prescription medication for obesity that has faced supply issues. Its manufacturer, Novo Nordisk, is increasing production capacity in 2023.
AbbVie Submits sNDA for Linzess for Children and Adolescents
If approved, Linzess would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age.
FDA Grants Six Months Pediatric Exclusivity for Eylea
Eylea is being reviewed as a treatment for retinopathy in premature infants.
